

Augustinus D G Krol

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3955164/publications.pdf>

Version: 2024-02-01

31
papers

3,230
citations

430442

18
h-index

525886

27
g-index

31
all docs

31
docs citations

31
times ranked

3661
citing authors

#	ARTICLE	IF	CITATIONS
1	Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2015, 373, 2499-2511.	13.9	474
2	Long-Term Risk of Second Malignancy in Survivors of Hodgkin's Disease Treated During Adolescence or Young Adulthood. <i>Journal of Clinical Oncology</i> , 2000, 18, 487-487.	0.8	416
3	Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1061-1069.	5.1	385
4	Cardiovascular Disease After Hodgkin Lymphoma Treatment. <i>JAMA Internal Medicine</i> , 2015, 175, 1007.	2.6	373
5	Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 235-243.	0.8	339
6	Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 464-474.	5.1	242
7	Risk for Valvular Heart Disease After Treatment for Hodgkin Lymphoma. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	224
8	Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials. <i>Journal of Clinical Oncology</i> , 2006, 24, 3128-3135.	0.8	216
9	Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 274-283.	5.1	151
10	Risk of Diabetes Mellitus in Long-Term Survivors of Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 3257-3263.	0.8	72
11	Risk of multiple primary malignancies following treatment of Hodgkin lymphoma. <i>Blood</i> , 2014, 124, 319-327.	0.6	58
12	Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma. <i>JAMA Oncology</i> , 2021, 7, e205865.	3.4	45
13	Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients. <i>Journal of the National Cancer Institute</i> , 2021, 113, 760-769.	3.0	45
14	Extrameningeal solitary fibrous tumors—surgery alone or surgery plus perioperative radiotherapy: A retrospective study from the global solitary fibrous tumor initiative in collaboration with the Sarcoma Patients EuroNet. <i>Cancer</i> , 2020, 126, 3002-3012.	2.0	39
15	Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal Hormone Exposure. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 843-853.	0.4	36
16	Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma. <i>Blood</i> , 2019, 133, 1130-1139.	0.6	29
17	Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors. <i>British Journal of Cancer</i> , 2017, 117, 306-314.	2.9	26
18	Primary sarcoma of the heart: case report and literature review. <i>Journal of Cardiothoracic Surgery</i> , 2020, 15, 104.	0.4	25

#	ARTICLE	IF	CITATIONS
19	Comparing causes of death of Hodgkin lymphoma and breast cancer patients between medical records and cause-of-death statistics. <i>Clinical Epidemiology</i> , 2018, Volume 10, 1523-1531.	1.5	5
20	Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer. <i>Cancer Medicine</i> , 2019, 8, 190-199.	1.3	5
21	A phase II study on the neo-adjuvant combination of pazopanib and radiotherapy in patients with high-risk, localized soft tissue sarcoma. <i>Acta Oncologica</i> , 2021, 60, 1557-1564.	0.8	5
22	Therapy-Related Imaging Findings in Patients with Sarcoma. <i>Seminars in Musculoskeletal Radiology</i> , 2020, 24, 676-691.	0.4	5
23	Elevated resting heart rate is a marker of subclinical left ventricular dysfunction in Hodgkin lymphoma survivors. <i>IJC Heart and Vasculature</i> , 2021, 35, 100830.	0.6	4
24	The Influence of Personalised Sarcoma Care (PERSARC) Prediction Modelling on Clinical Decision Making in a Multidisciplinary Setting. <i>Sarcoma</i> , 2021, 2021, 1-6.	0.7	4
25	Single-institution clinical experience using robust intensity modulated proton therapy in chordoma and chondrosarcoma of the mobile spine and sacrum: Feasibility and need for plan adaptation. <i>Radiotherapy and Oncology</i> , 2022, 166, 58-64.	0.3	3
26	Cardiovascular diseases after Hodgkin lymphoma treatment: 35-year disease risk and sequence of events.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9505-9505.	0.8	2
27	Cause-specific mortality among patients with Hodgkin lymphoma (HL) up to 40 years after treatment.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9517-9517.	0.8	2
28	In Reply to Wang et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1291-1292.	0.4	0
29	Treatment-specific risks of second malignancy and cardiovascular disease in Hodgkin lymphoma survivors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9584-9584.	0.8	0
30	Long-term survival of gastrointestinal cancer diagnosed in Hodgkin lymphoma survivors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 40-40.	0.8	0
31	Impaired Global Longitudinal Strain Is Associated with Cardiovascular Events in Hodgkin Lymphoma Survivors. <i>Cancers</i> , 2022, 14, 2329.	1.7	0